The interaction between human natural killer (NK) cells and yeast cells of Cryptococcus neoformans was investigated because experiments in mice indicated that NK cells inhibited the growth of C. neoformans. Strains of C. neoformans serotype A that differed in both resistance to alveolar macrophages and the size and composition of their capsules were evaluated. Human NK cells, which were isolated from normal peripheral blood, were activated by preincubation with interleukin-2 and alpha interferon to generate lymphokineactivated killer (LAK) cells. Yeast ceUs of C. neoformans were incubated with effector cells (NK or LAK cells); and inhibition of yeast cell growth was measured at 4, 8, and 24 h by comparing quantitative plate counts with controls consisting of yeasts in the absence of effector cells. The cytolytic activity of effector cells against target cells was confirmed by the release of radiolabel from -5Cr-labeled K-562 tumor cells. Neither NK nor LAK cels inhibited the growth of 13 strains of C. neoformans at effector to target cell ratios of as high as 500:1. Monocytes, which were isolated from the same populations of leukocytes as the NK ceUs, inhibited the growth of two strains of C. neoformans at effector to target ceUl ratios of 100:1 (92 and 46% inhibition), 50:1 (87 and 17%), and 1:1 (49 and 0%). NK ceUls could inhibit the growth of C. neoformans by an antibody-dependent cellular cytotoxicity mechanism in the presence of rabbit anticryptococcal antiserum at dilutions up to 1:4,000. Purified capsular polysaccharide of C. neoformans had no effect on the viability or tumoricidal activity of NK or LAK cels. These data suggest that human NK and LAK cells are not impaired by C. neoformans, and in the absence of antibody, which is rarely detectable in patients, they afford much less protection against C. neoformans than monocytes do.
Cryptococcus neoformans is a significant cause of opportunistic infection in patients with impaired cell-mediated immunity (20, 21) . Cryptococcal meningitis occurs more frequently in patients who have received corticosteroids, patients with hematologic malignancies, and patients with acquired immune deficiency syndrome (AIDS), in whom the incidence of cryptococcosis is estimated at 10 to 15% (9, 16) .
Clinical and experimental evidence indicates that the crucial host defense mechanisms against cryptococcosis involve T-cell responses and the activities of phagocytes (2, 3, 6, 7, 18, 20, 33) . However, recent murine studies suggest that natural killer (NK) cells may also represent an important mechanism of resistance against C. neoformans (24, 25) .
Murine NK cells are able to inhibit the growth of yeast cells of C. neoformans, both in vitro (24, 25) and in vivo (13, 19) , and the inhibition is enhanced by anticryptococcal antibody (25) . Murine NK cells also inhibit the growth of other fungi, including Paracoccidioides brasiliensis (15) and Candida albicans (1) . However, human NK cells do not inhibit C. albicans (34) .
The purpose of this study was to evaluate the effectiveness of human NK cells and lymphokine-activated killer (LAK) cells against C. neoformans. Strains of C. neoformans that differed in several defined biological and biochemical properties were compared for differences in their susceptibilities to inhibition of growth by resting NK and LAK cells. In addition, strains of C. neoformans that were recently isolated from patients with and without AIDS were compared for their susceptibilities to LAK cells, growth rates, and sizes of their capsules and cells. The growth inhibitory activity of three effector cells-resting NK cells, LAK cells, and monocytes-was compared, and the influence of rabbit MATERIALS AND METHODS Strains of C. neoformans. Seven previously characterized strains of C. neoformans serotype A and six recent clinical isolates of C. neoformans were studied. The strains designated 6, 15, 98, 110, and 145 are stable variants of serotype A that differ in (i) the sizes of their capsules; (ii) the degree to which they are phagocytized and killed by alveolar macrophages (2, 3) ; and (iii) the relative molecular size, composition, and binding capacity of their CPSs (28, 29) . Strain 184, also serotype A, was generously donated by Juneann W. Murphy (22) . The capsule-free mutant, strain 602, was a gift from Thomas R. Kozel (17) . The six recent clinical isolates were obtained from the Clinical Mycology and Mycobacteriology Section of the Clinical Microbiology Laboratory at Duke Hospital and designated with the accession numbers 1188, 1218, 1458, 1508, 1948, and 1988 ; these strains were evaluated within 6 months or less from the time of their recovery from patient specimens. The underlying diseases of the patients and the specimens from which these strains were isolated, the sizes of the yeast cells and capsules, and the growth rates of these strains are presented in Table 1 .
All yeasts were maintained at 37°C on slants composed of 2% glucose and 1% yeast extract (Difco Laboratories, Detroit, Mich.) (GYE) with 2% agar and were transferred at biweekly intervals. The diameters of the yeast cells and capsules were determined by microscopic examination of India ink preparations. Each isolate was cultured at 37°C for 3 days on GYE slants, and at least two investigators, on (30) . Venous blood was collected in 20 U of heparin per ml and centrifuged at 500 x g for 30 min, and the resulting buffy coat was removed. Leukocytes were suspended in medium that was composed of RPMI 1640 (GIBCO Laboratories, Grand Island, N.Y.) and supplemented with L-glutamine, 25 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) buffer, 100 U of penicillin per ml, and 100 ,ug of streptomycin per ml (RPMI). The cells were layered on a discontinuous gradient of FicollHypaque (LSM; Organon Teknika, Durham, N.C.) and centrifuged at 500 x g for 30 min. The cells at the resulting interface were removed, washed, and suspended in RPMI with 10% (vol/vol) heat-inactivated fetal bovine serum (GIBCO) (RPMI-FBS). T cells were removed by erythrocyte-rosette depletion with 2-aminoethylisothiouraniumbromide hydrobromide-modified sheep erythrocytes (27) . The remaining cells were washed and suspended in RPMI-FBS. Adherent cells were depleted by incubation in 75-cm2 plastic culture flasks (Corning Glass Works, Corning, N.Y.) for 60 min at 37°C under 5% CO2. The flasks were washed three times with warm phosphate-buffered saline at pH 7.4 to collect nonadherent cells, which were subsequently fractionated on a two-step discontinuous Percoll (Pharmacia Fine Chemicals, Piscataway, N.J.) gradient. The upper Percoll layer had a density of 1.057 g/ml and a refractive index of 1.3420 (at 23°C); the density of the lower layer was 1.064 g/ml and the refractive index was 1.3433. Gradients were centrifuged at 500 x g for 30 min, and the NK-enriched population of cells was collected from the interface of the two Percoll layers. These resting NK cells were resuspended, washed, counted in a hemacytometer, and adjusted to 106 cells per ml of RPMI-FBS. NK preparations typically had the following phenotypes: >60% Leu-7 (CD57) positive, >75% (CD56) positive, >85% OKM1 (CD11b) positive, >60% Leu-llb (CD16) positive, <1% M02 (CDw14) positive, <5% OKT3 (CD3) positive, <15% Bi (CD20) positive, and <20% 4F2 (activation antigen) positive (data not shown) (30) .
To activate the resting NK cells, 50 U of interleukin-2 per ml (8) and 50 U of alpha interferon per ml (31) 100 ,ul of RPMI with 10% normal human serum, which was collected from healthy volunteers. Yeasts were harvested as described above and suspended in RPMI at 3 x 105 yeast cells per ml. Samples of 10 or 20 ,u of this suspension were added to the wells to yield monocyte to yeast (E:T) ratios of 100:1 and 50:1, respectively. An E:T ratio of 1:1 was achieved by adding 100 pI of yeasts at 3 x 106/ml of RPMI with 10% normal human serum. After incubation for 4 h at 37°C in 5% C02, 100 plA of 0.25% (vol/vol) Triton X-100 was added to all wells to lyse the monocytes and release phagocytized yeast cells, and the plates were reincubated for 15 min. Growth at each ratio was assessed in triplicate and compared with growth in corresponding control wells containing only yeast cells in RPMI with 10% normal human serum. The wells were washed three times with sterile water, the washes were pooled and serially diluted, and portions of the final dilution were placed in petri plates to which molten GYE was added as described above. Microscopic examination of wells and wash fluids revealed that the monocytes were completely lysed by Triton X-100. Residual cell fragments were not visible in the wells or the wash fluids. After 3 days of incubation at 37°C, the number of CFU was enumerated and the percentage of control growth was calculated as described above. Preliminary experiments confirmed that, under these conditions, Triton X-100 had no effect on the viability or clumping of the yeast cells.
Effect of the C. neoformans CPS on NK and LAK cells. To determine whether the CPS of C. neoformans had any effect on the effector cells, resting NK and LAK cells were exposed to purified CPS from strain 110 (29) and tested for tumoricidal activity. CPS was dissolved in RPMI at 1,000 pug/ml. Resting NK or LAK cells were suspended at 106 cells per ml in a final volume of 300 pl of RPMI containing 0, 100, 200, or 400 pug of CPS per ml. The tubes were incubated for 18 h at 37°C under 5% CO2. Ten minutes before the 18-h incubation period ended, CPS was added at the same concentrations to a set of effector cells that had been incubated without CPS. The effector cells from both 0-and 18-h incubations in CPS were then tested for tumoricidal activity as described above at E:T ratios of 10:1 and 2.5:1. Triplicate wells were assayed for each E:T ratio, concentration of CPS, and effector cell that was tested.
Effect of anti-C. neoformans antiserum on the inhibition of growth of C. neoformans by NK cells. The participation of NK cells in antibody-dependent cellular cytotoxicity against C. neoformans was evaluated. Rabbit anti-C. neoformans antisera, which were generously donated by Errol Reiss, were diluted in RPMI-FBS and added to the NK inhibition assay described above at final concentrations of 1:1,000, 1:2,000, and 1:4,000. The dilutions of antisera were added in volumes of 50 ,u to wells containing NK cells, and then yeast cells of strain 184 were added. The assay of antibody-dependent cellular cytotoxicity was tested at NK to yeast cell ratios of 500:1, 50:1, and 10:1. For the 50:1 ratio, yeasts cells were suspended at 105 yeasts per ml in RPMI-FBS, and 20 pul was added to the appropriate wells; for the 10:1 ratio, 10 (26) . Effector cells were harvested from the fraction of cells with an intermediate density in Percoll; this fraction has been shown to exhibit 80 to 90% of the NK cell cytolytic potential, as assayed by a 4-h chromium release assay (14) . In each experiment in which the activities of NK and LAK cells were compared, the same population of cells was used. Resting NK cells were incubated overnight in RPMI-FBS alone, and LAK cells were generated by incubating NK cells with interleukin-2 and alpha interferon. The following day, the tumoricidal activity of resting NK and LAK cells was evaluated at E:T ratios of 2.5:1, 5:1, and 10:1.
As indicated in Table 2 (28, 29) , were compared to detect any strain differences in resistance to growth inhibition by NK cells. Strain 184 was used in the murine NK cell studies (23, 25) . The capsule-free mutant, strain 602, was also included (17, 18) . Yeast (target) cells of each strain were tested against both resting NK and LAK effector cells at E:T ratios of 500:1 and 100:1, and growth was quantified in the presence and absence of effector cells after incubation for 4, 8, and 24 h. (Preliminary experiments with NK cells showed no inhibition at E:T ratios of 10:1 and 50:1.)
The percentage of control growth of these strains in the Table 4 . These strains varied with source and underlying disease of the patient, as well as capsule and cell size (Table 1) . These strains entered logarithmic growth between 4 and 8 h, which was earlier than that of the other strains.
NK and LAK viability was determined by trypan blue exclusion and exceeded 90% for all time periods and experiments, with or without the presence of yeast cells.
Inhibition of growth of C. neoformans by monocytes. To confirm that human monocytes were able to inhibit the growth of C. neoformans (6) and to provide a control for the assay of growth inhibition, human monocytes were recovered from the same blood samples from which NK cells were obtained. Both the encapsulated strain 98 and the capsulefree strain 602 were inhibited by monocytes, as shown in Table 5 . Killing occurred at E:T ratios of 100:1 and 50:1 for both strains and at 1:1 for strain 98. The assays were highly reproducible, and growth inhibition correlated with the E:T ratios. (Triton X-100, which was added to lyse the monocytes and release phagocytized yeast cells, did not affect the viability of the yeasts, and no clumping of yeast cells occurred in experimental dilutions.) Similar to the recent report by Levitz and DiBenedetto (18) , the encapsulated yeasts were inhibited to a significantly greater extent than the capsule-free strain.
Effect of CPS on NK and LAK cells. To determine whether the tumoricidal activity of the NK and LAK cells was affected by C. neoformans, purified CPS from C. neoformans 110 (29) was added to both effector cells at final concentrations of 100, 200, and 400 ,ug/ml. The effector cell populations were split and incubated with CPS for either 10 min or 18 h, to discriminate between a potential binding or metabolic effect, respectively, and the cells were assayed for tumoricidal activity against radiolabeled K-562 cells at E:T ratios of 2.5:1 and 10:1. CPS had no effect on the viability of the effector cells. At all of the CPS concentrations, as well as both exposure times and E:T ratios, CPS had no significant effect-neither inhibition nor enhancement-on the tumoricidal activity of the NK or LAK cells.
Effect of anti-C. neoformans antibodies on the inhibition of growth of C. neoformans by NK cells. In the presence of rabbit anticryptococcal antiserum, human NK cells functioned as effectors in an antibody-mediated cellular cytotoxicity reaction that inhibited the growth of C. neoformans. The antiserum was tested at final dilutions of 1:1,000, 1:2,000, and 1:4,000, and NK to yeast cell ratios of 10:1, 50:1, and 500:1 were evaluated. Control wells contained similar mixtures of NK cells, yeasts, and nonimmune rabbit serum. After incubation for 4 or 8 h, growth of the yeast cells was quantified and compared with growth in wells lacking NK cells. At the E:T ratio of 500:1, the CFU of C. neoformans 184 per well was reduced to 48 to 51% of control growth in all concentrations of antiserum after 4 h and to 18 to 24% by 8 h. With the antiserum diluted 1:2,000, the numbers of viable yeasts remaining at 4 h were 65, 27, and 50% of the controls at E:T ratios of 10:1, 50:1, and 500:1, respectively. Growth of the yeast cells was not inhibited by NK cells and nonimmune rabbit serum. Yeast cells were neither clumped nor killed in the presence of either serum alone, as the number of CFU per well was similar among wells containing yeasts in antiserum, nonimmune serum, or RPMI-FBS.
DISCUSSION
Neither human resting NK nor LAK cells had any effect on the growth of C. neoformans in vitro. Similar, Percollfractionated effector cells from mice have been reported to inhibit the growth of C. neoformans 184, and inhibition of these yeast cells was augmented by the addition of anticryptococcal antibody (23) (24) (25) . In this investigation, the effect of human NK cells on growth of C. neoformans was evaluated at 4, 8, and 24 h. The 4-and 8-h time periods were selected to detect any early reduction in the inoculum before significant growth of surviving yeasts could mask inhibition. (The doubling time of all the strains tested was similar and averaged ca. 6 h.) The kinetics of tumor cell killing suggested that any growth inhibition would have been evident by 24 h. To optimize conditions for growth inhibition, ratios of NK to yeast cells of 500:1 and 100:1 were tested. Similar and smaller ratios were effective in the murine system (23, 24) .
The efficacy of purified human NK and LAK cells was confirmed by quantifying tumoricidal activity against K-562 cells, the prototypic tumor target for human NK cell cytotoxicity. Both effector cells demonstrated appreciable cytotoxic activity, and treatment of the NK cells with interleukin-2 and alpha interferon significantly increased this activity ( Table 2) .
A number of previously characterized and recently isolated strains of C. neoformans were investigated to explore potential strain variation in inhibition of growth by human NK and LAK cells. The strains varied in several properties, including (i) the dimensions of the yeast cells and capsules (Table 1) ; (ii) the chemical composition, molecular size, and binding characteristics of their CPSs (28, 29) ; (iii) resistance of the cells to phagocytosis and killing by alveolar macrophages (2, 3); and (iv) their source and association with patients with AIDS ( Table 1 ). All the strains had similar rates of growth (Table 1) . None of the strains was significantly inhibited by NK or LAK cells at any of the incubation times or effector to yeast cell ratios, including strain 602, a capsule-free mutant, and strain 184, which was inhibited by murine NK cells (23, 24) .
Six of the strains of C. neoformans were tested within 6 months of their isolation from patients and provided a comparison of strains from patients with and without AIDS ( Table 1) . Strains from patients with AIDS have been reported to have smaller capsules and overall sizes (4, 5) , and patients with AIDS have been reported to have impaired NK cell activity (32) . The strains from patients with AIDS used in this study were poorly encapsulated and relatively small in total (capsule plus cell) size, but they were not significantly different from the strains from other patients (Table 1) . Although the growth rates of all the strains were similar, the six recently isolated strains had shorter lag phases than did the other strains in both GGA-B and RPMI-FBS media. These strains were equally resistant to LAK cells (Table 4 ).
The studies of murine NK activity found no correlation between capsule size and inhibition of growth of C. neoformans strains (23) . Murine NK cells recognize and bind a component of C. neoformans that is located at the cell wall, beneath the capsule (24).
C. neoformans had no effect on the viability or tumoricidal activity of NK and LAK cells. Whole yeast cells did not reduce the viability of the effector cells during the 24-h growth inhibition assay. The CPS from strain 110 was added to NK and LAK cells at concentrations of 100, 200, or 400 ,ug/ml, and cytotoxicity was measured immediately or after incubation for 18 h. No inhibitory or stimulatory effect on NK or LAK activity was observed under any of the conditions tested.
The inhibition of growth of C. neoformans by monocytes provided a positive control for the assay of growth inhibition. Both encapsulated and capsule-free yeasts were inhibited (Table 5 ). The results were highly reproducible, and killing correlated with increasing ratios of monocytes to yeast cells. The percent growth inhibition was comparable to those presented in previous reports (6, 18) . In confirmation of the results of Levitz and DiBenedetto (18) , the capsulefree strain was more resistant than the encapsulated strain.
The enhancement of growth inhibition by NK cells in the presence of small amounts of rabbit anti-C. neoformans antibody was dramatic. This antiserum had a high titer of anti-CPS antibodies, as detected by indirect immunofluoresence (data not shown), which would facilitate contact between NK and yeast cells. The antibody alone had no effect on the determination of yeast growth. However, since specific antibody is rarely detectable or produced by patients with cryptococcosis (11, 12) , the significance of NK-mediated, antibody-dependent cellular cytotoxicity as an important defense against cryptococcosis is questionable.
Results of this investigation suggest that human NK and LAK cells are not an important component of the natural immune response against C. neoformans. Murine and human NK cells exhibit significant differences in their cytotoxicity for C. neoformans and perhaps other microbial targets. Other peripheral host defenses, such as neutrophils, monocytes, and antibody-enhanced NK cells, are more effective anticryptococcal defenses. These defense mechanisms and strain differences in susceptibility to them are under investigation.
